SP-0103: Defining the need for systemic treatment, e.g. which agents and when  by Bourhis, J.
S40  2nd ESTRO Forum 2013	
as those of the Cancer Data Standards Registry and Repository (caDSR) 
need to be adopted more widely to ensure uniformity. For a given 
biomarker, a classification needs to include the type of marker 
(whether diagnostic, prognostic, predictive, or companion diagnostic), 
the marker’s characteristics (e.g. what it is measuring in terms of 
pathways, or receptor status, at the molecular level), the physiologic 
compartment source (e.g. blood, urine, tissue, CSF, bone marrow), 
and the setting including clinical presentation and scenario specificity 
(i.e. when the marker is useful and relevant).  For the latter the 
decision will also need to address whether new diseases (e.g. HPV-
driven cancer) should continue to be combined with the classic 
version of oropharyngeal cancer since emerging data has underlined 
the separate nature of these processes at the etiology, clinical, 
pathological, molecular, and outcome levels. This may also extend to 
whether the TNM classification should even be the same for both 
diseases. 
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In the near future rational individualisation of radiation dose 
prescription will be possible. Current technology now allows the 
distribution of radiation dose to be tightly controlled and advances in 
our understanding of the biology of the disease will lead to 
individualisation of radiation dose delivery both within individual 
patients and between different patients. 
Functional imaging is at the present time the most likely candidate 
technology to influence our choice of individualising the dose 
distribution, however a number of unanswered questions remain 
before this can become a reality.  
This presentation will review the current state of this area of research 
and discuss likely forward directions of research. Clinical trials to 
evaluate these technologies will be discussed.  
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Radiofrequency ablation (RFA) is regarded as the primary ablative 
modality for local tumour destruction at most institutes.  It involves 
delivery of high-frequency, in the range of 375 to 500 kHz, alternating 
electrical current into the target tissue through a needle electrode.  
Electrical current passes back and forth through the body between the 
electrode and some grounding pads putting on the skin of the thighs.   
The high frequency of alternating current causes rapid movement of 
the ions or charged molecules within the cells in the tissue 
surrounding the electrode.  Heat is produced by friction during the 
rapid movement of these molecules. Temperature in excess of 50 °C 
produces coagulative necrosis.  A 2 to 5 cm spherical thermal injury 
can be produced with each ablation, depending on the design of the 
needle electrode. 
The main aim of thermal tumour ablation therapy is to destroy an 
entire tumour, with a 1 cm margin, in a minimally invasive fashion 
without damaging adjacent vital structures.  Each ablation requires 
exact placement of electrode in the tumour.  Any radiofrequency 
needle electrodes can be inserted percutaneously, under laparoscopic 
guidance or during laparotomy.  With percutaneous approach, the 
electrodes can be placed under sonographic, CT, or MR guidance.  
The major complications associated with RFA occur in 2.2–3.1% of 
patients. The minor complication rate ranges from 5% to 8.9%. 
Complications are divided into 3 different types: thermal damage 
(gastrointestinal perforation, biliary stenosis, cardiac tamponade and 
grounding pad burns), mechanical complications (injuries to bile ducts 
and vessels, tumour seeding and hemorrhage), and septic 
complications (abscess and peritonitis). Treatment of lesions adjacent 
(< 1 cm) to the hepatic hilum increases the risk of thermal injury of 
the major biliary tract and represents a relative contraindication to 
RFA. Thermal ablation of lesions adjacent to hepatic vessels increases 
the risk of incomplete treatment of the neoplastic tissue close to the 
vessel due to heat loss or heat sink effect. 
From the recent data on long-term survival of nonsurgical patients 
(due to comorbidity, patient refusal or unfavourable anatomy) with 
colorectal liver metastases (CRLM) who underwent RFA, the 5-year 
survival rate ranges 24–44%. These figures are substantially higher 
than those obtained with any chemotherapy regimens and provide 
indirect evidence that RFA therapy improves survival in patients with 
limited hepatic metastatic disease. 
Currently, liver resection (LR) is regarded as the gold standard 
treatment for resectable CRLM. One of the greatest criticisms for the 
utilization of RFA for treatment of CRLM has been a concern of high 
local recurrence at the RFA site. Local recurrence rates after RFA in 
the literature have been quite variable and range from 4% to 55%.  A 
recent meta-analysis found the overall local recurrence rate to be 
14.7%. 
Multiple studies have been published comparing RFA to LR for 
treatment of CRLM. In a recent published meta-analysis, 3-year  and 
5-year disease free survival as well as 3- year and 5-year overall 
survival are significantly higher in the LR group.  
Based on these retrospective reports, several authors have concluded 
that RFA is not equivalent to surgical resection and therefore should 
not be used to treat lesions that are otherwise resectable. Due to the 
retrospective nature of these studies, and the significant bias in 
patient selection, these results are difficult to interpret and the role 
of RFA remains biased. In addition, these retrospective studies are not 
randomized. 
The use of RFA does not prevent simultaneous or subsequent use of 
other, potentially complementary, treatments. Combining with other 
treatment modality is probably the future direction for RFA in the 
treatment of CRLM. 
There is limited data on the use of RFA in treating hepatic metastases 
from non CRLM.  The conclusion from those published 
studies employing RFA to treat non CRLM is that RFA is regarded as an 
adjunct to resection and unresectable lesions that demonstrate 
positive response after chemotherapy.   
 
SP-0105   
Radiotherapy for liver metastases 
M. Hoyer1 
1Aarhus University Hospital, Department of Oncology, Aarhus C, 
Denmark  
  
The present evidence for local ablation of liver oligo-metastases is 
limited. No randomized controlled trial has ever proven the efficacy 
of local ablation on survival, and the evidence is even poorer when it 
comes to comparisons of the different ablation methods. Surgical 
resection has by tradition been the preferred therapy for liver oligo-
metastases and radiofrequency ablation (RFA) is frequently used for 
treatment of inoperable patients. Stereotactic body radiation therapy 
(SBRT) is most often number three in line and has been used for 
therapy of medical inoperable patients and patients who are not 
amendable for surgery or RFA for technical reasons. These reasons are 
most often related to size of the metastases or the anatomical 
distribution in the liver. Where SBRT has been standard of care in 
therapy of patients with limited stage non-small cell cancer and 
lungmetastases for some time, the introduction of SBRT in the 
treatment of tumors in the liver has been characterized by hesitation.  
A number of retrospective and few prospective studies have been 
published on SBRT for liver metastases. In general, studies are 
characterized by considerably heterogeneity concerning patient 
selection. Retrospective studies often include a variety of tumor types 
with variability of number and size of the metastases and this 
translates into a broad variability in outcome. The most frequent 
tumor type investigated is colorectal carcinoma (CRC) metastases, but 
there are studies including almost all tumor types. Some studies show 
that survival outcomes are not different for CRC and non-CRC 
patients. Most studies demonstrate high local control rates ranging 80-
90% in SBRT for liver metastases. Treatment techniques, doses and 
fractionation varies between the studies, but an effect of dose 
escalation on the local control is fairly consistent. It is generally 
accepted that when using a 3 fraction schedule, the prescription dose 
should be at least 48 Gy.  
The morbidity after SBRT for liver metastases is mild to moderate. 
Most often it is limited to temporary abdominal wall pain, rib fracture 
and erythema. Severe morbidity related to exposure of the stomach or 
bowel and hepatic failure due to radiation hepatitis, a few being 
fatal, have been reported. 
Novel radiotherapy techniques have contributed to the improved 
precision in delivery of largeradiation doses to defined targets by 
